Thyroid cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BRAF 15
• RET 8
• PI3K 0
• TP53 0
• TERT 0
• MAPK 1
• GLP-1 1
• AKT 0
• PTEN 0
• STAT3 0
• mTOR 0
• NTRK 2
• PD-1 5
• RAS 1
• ERK 0
• MEK 1
• PSMA 1
• ALK 1
• EGFR 3
• VEGF 2
• PD-L1 0
• JAK 0
• KRAS 1
• CTNNB1 0
• NRAS 2
• NRF2 0
• PPAR 0
• TROP2 3
• AMPK 0
• DLL3 2
• HIF-1 0
• PIK3CA 0
• ABL1 0
• DPP-4 0
• IL-6 1
• METTL3 0
• TNF 0
• YAP 0
• AXL 1
• EZH2 0
• FGFR 0
• JNK 0
• MET 1
• MYC 0
• PKM2 0
• ROS1 1
• SGLT2 0
• STING 0
• ATM 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CDKN2A 0
• CGRP 0
• CTLA-4 0
• CXCR4 0
• FAK 0
• GPX4 0
• HMGB1 0
• IDH 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €2,497,392· until Dec 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Chemotherapy-induced Alopecia - Relief Managed by Engineered Silk (CARMESilk)

  Friedrich-Schiller-Universität Jena· Jena, Germany· EU contribution €401,232· until Sept 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

  Sveuciliste U Splitu Medicinski Fakultet· Split, Croatia· EU contribution €4,937,275· until Dec 2028· 2 countries

3 of 3 running projects, newest first. Listed amounts together: €7.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

  NCT04418167· JS InnoPharm, LLC· Updated 3 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

• FPSA, a potential risk factor for thyroid nodules by gender: A cohort study in China.

  Int J Biol Markers, Oct 2026

• Radiofrequency versus microwave ablation for non-functioning benign thyroid nodules: a single-institution comparative cohort study.

  Endocrine, Oct 2026

• Second primary malignancy risk following radioactive iodine therapy for thyroid cancer: a population-based matched cohort study in Taiwan.

  Eur J Endocrinol, Oct 2026

• Expanding the Molecular Data of DICER1-Related Tumor Predisposition: Novel Germline Variants in an Argentine Pediatric Cohort.

  Hum Mutat, Sept 2026

• Validation of a thyroid malignancy risk calculator in a Portuguese cohort.

  Endocrine, Sept 2026

• Beyond Tumor Diameter: Exploratory Cohort-Derived Calcitonin Secretory Categories and Invasive Pathology in Medullary Thyroid Carcinoma.

  Curr Oncol, Sept 2026

• Sex and Mortality Among Patients with Papillary Thyroid Cancer.

  JAMA Netw Open, Sept 2026

• Cancer Risk Among Young Adults With Clinically Diagnosed Fatty Liver Disease: A Nationwide Cohort Study in South Korea.

  Cancer Med, Sept 2026

• Radiation Risk of Screening-Detected Diffuse Goiter in a Belarusian Cohort Exposed as Children or Adolescents to Iodine-131 after Chernobyl.

  Cancer Epidemiol Biomarkers Prev, Sept 2026

• APOC1-Associated VLDL-Pathway Dysregulation in Papillary Thyroid Carcinoma: A Reproducible Cross-Cohort Transcriptomic Signature Associated With the Diagnostic-to-Treatment Interval.

  Chem Biol Drug Des, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.